Dainippon Sumitomo Plans To Buy U.S. Biotech For Potential $2.63 Billion
This article was originally published in PharmAsia News
Executive Summary
Dainippon Sumitomo Pharma said it plans to pay $200 million for U.S. biotech start-up Boston Biomedical in a deal that could reach as much as $2.63 billion with milestone payments added.